SFM
ELDN icon

Sphera Funds Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Sphera Funds Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,200
Closed -$84.6K – 121
2025
Q2 		$84.6K Buy
+31,200
New +$93.6K 0.02% 108

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Sphera Funds Management's ELDN Position: Q2 2026 in Review

Sphera Funds Management reduced its Eledon Pharmaceuticals (ELDN) stake by 33% in Q2 2026, selling an estimated $2.11M and leaving 1,191,187 shares worth $4.69M. The position accounts for 0.61% of the portfolio, ranked #53.

Sphera Funds Management first reported a position in ELDN in Q3 2014 and has held it in 12 quarters since. The position peaked at $10.5M in Q4 2024. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Sphera Funds Management held 1,191,187 shares of Eledon Pharmaceuticals worth $4.69M as of Q2 2026.
  • Sphera Funds Management sold 580,944 Eledon Pharmaceuticals shares in Q2 2026, an estimated $2.11M.
  • Eledon Pharmaceuticals made up 0.61% of Sphera Funds Management's portfolio in Q2 2026, its #53 holding.
  • Sphera Funds Management first reported a position in Eledon Pharmaceuticals in Q3 2014 and has held it in 12 quarters since.
  • Sphera Funds Management's Eledon Pharmaceuticals position peaked at $10.5M in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.